Publication:
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Simple item page
dc.contributor.authorYildirim M. E.
dc.contributor.authorKaradurmus N.
dc.contributor.authorOkten I. N.
dc.contributor.authorTÜRK H. M.
dc.contributor.authorUrakci Z.
dc.contributor.authorArslan C.
dc.contributor.authorCelik S.
dc.contributor.authorDANE F.
dc.contributor.authorŞENDUR M. A. N.
dc.contributor.authorBİLİR C.
dc.contributor.authoret al.
dc.contributor.institutionauthorTÜRK, HACI MEHMET
dc.date.accessioned2024-05-07T21:50:18Z
dc.date.available2024-05-07T21:50:18Z
dc.date.issued2024-04-13
dc.description.abstractBackgrounds and Objectives Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311).Materials and Methods In this retrospective analysis, records from 28 centers were collected, and histopathological, molecular, and clinical characteristics were documented. Patients were categorized into groups based on their second-line biological treatments: anti-EGFR (Group A and Group B, panitumumab and cetuximab) and anti-VEGF (Group C, bevacizumab and aflibercept). They were then compared within these groups.Results A total of 588 patients with documented RAS wild-type status were evaluated. The median OS was 15.7, 14.3 and 14.7 months in Group A, Group B and Group C, respectively (p = 0.764). The median PFS of the patients in second-line setting that received panitumumab, cetuximab and bevacizumab/aflibercept were 7.8, 6.6 and 7.4 months, respectively (p = 0.848).Conclusion According to the results of our real-life data study, there is no significant difference in efficiency between the combination of biological agent and chemotherapy used in the second-line treatments.
dc.identifier.citationYildirim M. E., Karadurmus N., Okten I. N., TÜRK H. M., Urakci Z., Arslan C., Celik S., DANE F., ŞENDUR M. A. N., BİLİR C., et al., "Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC", JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024
dc.identifier.doi10.1177/10781552241241004
dc.identifier.issn1078-1552
dc.identifier.pubmed38613329
dc.identifier.scopus85190527263
dc.identifier.urihttps://hdl.handle.net/20.500.12645/39260
dc.identifier.wosWOS:001201466900001
dc.relation.ispartofJOURNAL OF ONCOLOGY PHARMACY PRACTICE
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectPharmacology and Therapeutics
dc.subjectBasic Pharmaceutics Sciences
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectONCOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectLife Sciences (LIFE)
dc.subjectFarmakoloji
dc.subjectFarmakoloji, Toksikoloji ve Eczacılık (çeşitli)
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectFarmakoloji (tıbbi)
dc.subjectİlaç Rehberleri
dc.subjectPharmacy
dc.subjectPharmacology
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology (medical)
dc.subjectDrug Guides
dc.titleReal-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC
dc.typeArticle
dspace.entity.typePublication
local.avesis.idf2fa107b-2fe6-4452-ad88-4576b1b6710a
relation.isAuthorOfPublication1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isAuthorOfPublication.latestForDiscovery1b3a1540-7e57-405d-8a9d-f926d17dcc29
Files
Collections
Yayınlar - Eserler